Flurry of activity from the FDA is likely to continue

10/11/2010 | Los Angeles Times (tiered subscription model)

The FDA's Center for Drug Evaluation and Research issued 103 warning letters in 2009 for misleading labeling and other violations, up from 21 in 2006, and the agency is seeking the authority to issue mandatory product recalls. "I think the general approach has clearly been more warning letters, more regulatory activity, a much more rigorous approach to regulating products on the market," said Kenneth Kaitin, director of the nonprofit Tufts Center for the Study of Drug Development.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX